These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19664711)

  • 1. The role of the blood-CNS barrier in CNS disorders and their treatment.
    Palmer AM
    Neurobiol Dis; 2010 Jan; 37(1):3-12. PubMed ID: 19664711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the blood-brain barrier in CNS drug discovery.
    Jeffrey P; Summerfield S
    Neurobiol Dis; 2010 Jan; 37(1):33-7. PubMed ID: 19664709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the blood brain barrier in neurodegenerative disorders and their treatment.
    Palmer AM
    J Alzheimers Dis; 2011; 24(4):643-56. PubMed ID: 21460432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
    Löscher W; Potschka H
    Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.
    Gabathuler R
    Neurobiol Dis; 2010 Jan; 37(1):48-57. PubMed ID: 19664710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakdown of the blood brain barrier and blood-cerebrospinal fluid barrier is associated with differential leukocyte migration in distinct compartments of the CNS during the course of murine NCC.
    Alvarez JI; Teale JM
    J Neuroimmunol; 2006 Apr; 173(1-2):45-55. PubMed ID: 16406118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.
    Thorne RG; Pronk GJ; Padmanabhan V; Frey WH
    Neuroscience; 2004; 127(2):481-96. PubMed ID: 15262337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons.
    Kleine TO; Benes L
    Cytometry A; 2006 Mar; 69(3):147-51. PubMed ID: 16479603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questioning the role of actinfree Gc-Globulin as actin scavenger in neurodegenerative central nervous system disease: relationship to S-100B levels and blood-brain barrier function.
    Gressner OA; Schifflers MC; Kim P; Heuts L; Lahme B; Gressner AM
    Clin Chim Acta; 2009 Feb; 400(1-2):86-90. PubMed ID: 19000909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
    Shen DD; Artru AA; Adkison KK
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1825-57. PubMed ID: 15381336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting delivery of antiviral drugs to the brain.
    Strazielle N; Ghersi-Egea JF
    Rev Med Virol; 2005; 15(2):105-33. PubMed ID: 15546130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis.
    Nakamura M; Yamashita T; Ueda M; Obayashi K; Sato T; Ikeda T; Washimi Y; Hirai T; Kuwahara Y; Yamamoto MT; Uchino M; Ando Y
    Neurology; 2005 Oct; 65(7):1051-6. PubMed ID: 16217058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration.
    Taylor EM; Otero DA; Banks WA; O'Brien JS
    J Pharmacol Exp Ther; 2000 May; 293(2):403-9. PubMed ID: 10773009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of blood-brain barrier permeability.
    Rapoport SI
    J Drug Target; 1996; 3(6):417-25. PubMed ID: 8863135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-brain barrier and treatment of central nervous system tumors.
    Wiranowska M
    J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.